Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Doumas

Showing results (91-100 of 381) with videos related to

Pageof 39
Sort By:
Diabetes, Obesity & Metabolism|October 17, 2025
Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?Theocharis Koufakis, Pantelis Sarafidis, Apostolos Tsapas, et al.
European Journal of Internal Medicine|July 23, 2020
Erectile dysfunction and adherence to antihypertensive therapy: Focus on β-blockersAthanasios Manolis, Michael Doumas, Claudio Ferri, et al.
The American Journal of Cardiology|October 19, 2020
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of InterestDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Nefrologia|November 27, 2022
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: Foe or friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
Archives of Medical Sciences. Atherosclerotic Diseases|July 18, 2022
Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational studyDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemicDimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
Current Drug Targets|November 14, 2014
PDE-5 inhibitors: clinical pointsMichael Doumas, Antonios Lazaridis, Niki Katsiki, et al.
Coronary Artery Disease|November 30, 2021
Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetesDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
European Journal of Internal Medicine|December 31, 2021
"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?"Dimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 28, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery DiseaseDimitrios Patoulias, George Kassimis, Michael Doumas, et al.
Pageof 39

Showing results (91-100 of 381) with videos related to

Sort By:
Pageof 39
Diabetes, Obesity & Metabolism|October 17, 2025
Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?Theocharis Koufakis, Pantelis Sarafidis, Apostolos Tsapas, et al.
European Journal of Internal Medicine|July 23, 2020
Erectile dysfunction and adherence to antihypertensive therapy: Focus on β-blockersAthanasios Manolis, Michael Doumas, Claudio Ferri, et al.
The American Journal of Cardiology|October 19, 2020
Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of InterestDimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, et al.
Nefrologia|November 27, 2022
Acute kidney injury with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: Foe or friend?Dimitrios Patoulias, Christodoulos Papadopoulos, Fotios Siskos, et al.
Archives of Medical Sciences. Atherosclerotic Diseases|July 18, 2022
Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational studyDimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemicDimitrios Patoulias, Christodoulos Papadopoulos, Aristi Boulmpou, et al.
Current Drug Targets|November 14, 2014
PDE-5 inhibitors: clinical pointsMichael Doumas, Antonios Lazaridis, Niki Katsiki, et al.
Coronary Artery Disease|November 30, 2021
Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetesDimitrios Patoulias, Christodoulos Papadopoulos, George Kassimis, et al.
European Journal of Internal Medicine|December 31, 2021
"Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?"Dimitrios Patoulias, Christodoulos Papadopoulos, Asterios Karagiannis, et al.
The American Journal of Cardiology|January 28, 2022
Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery DiseaseDimitrios Patoulias, George Kassimis, Michael Doumas, et al.
Pageof 39